Transcutaneous nitroglycerine has previously been reported to be effective in the treatment of erectile dysfunction. We present our results with the drug in a randomised, placebo controlled, double-blind crossover study. The effect of the drug has been evaluated both under laboratory conditions and in a home study. Eighteen men were included in the study. No effect of nitroglycerine could be demonstrated under laboratory conditions by application of the Rigiscan Monitor1. In the home study there was no statistical signi®cant effect of transcutaneous nitroglycerine compared to placebo (P 0.2813).
Introduction
Through many investigations nitric oxide has been con®rmed to play a very important role as a neurotransmitter in the formation of penile erection in men.
The use of nitroglycerine in the treatment of angina pectoris is well-known. It is also known that the effect of nitroglycerine is caused by a dilatation of arteries and veins brought about by a relaxation of smooth muscles in the wall of the vessel. The exact mechanism of action on a molecular level is not yet comprehensively understood, but it is believed that a chain reaction following administration of nitroglycerine leads to the formation of nitric oxide. Therefore it seems reasonable to assume that nitroglycerine could have some effect in the management of erectile dysfunction.
In this study we report our results from a study of penile transcutaneous administered nitroglycerine. The effect of the drug has been evaluated both in a home study (subjective interpretation) and in laboratory surroundings (evaluation by use of the Rigiscan Monitor1).
Materials and methods
Eighteen men with different kinds of erectile dysfunction were included in the study (Table 1 ).
All men were unable to complete intercourse. Only men who had some kind of erectile response to intracavernosal injection of 30 mg of papaverine were included in the study. Papaverine was administered in the ®rst part of the study under laboratory conditions. Not all patients achieved a response at this occasion but all had responded to papaverine on a previous occasion. The penile blood pressure was measured for all patients. To exclude the most severe cases of arterial insuf®-ciency only men with a penile-brachial index above 60% were included in the study.
Men with arterial hypotension, former coronary occlusion, hypersensitivity to nitroglycerine and men who had used any kind of drug containing nitroglycerine within the last two months were excluded from the study.
From the medical history and a thorough medical examination the most probable diagnosis was established for each patient (Table 1 ). The age of the men ranged from 39±65 y (media 56 y). Some of the patients had an excessive use of tobacco or alcohol and others took medicine that could affect an erection. No attempts were made to change these conditions before the patients entered the study.
Discotrine1
Discotrine 10 mga24 h (3M Health Care Ltd., Loughborough, England) is a transparent plaster, oval in shape and measures 35 mm 6 50 mm. A total of 10 mg of glycerylnitrate is absorbed through the skin if the plaster is kept in place for 24 h. A steady state plasma concentration of 0.2 ngaml is achieved in approximately 2 h. In spite of the short plasma halflife of glycerylnitrate (approx 5 min) there will be only a slow decline in the plasma concentration in the ®rst hour after removal of the plaster. This is due to deliberation of glycerylnitrate already absorbed from the plaster to the skin. In this study we applied the plaster to the skin of the penis, although it is unknown if the site of application has any in¯uence on the local plasma concentration.
The Rigiscan Monitor1
The Rigiscan Ambulatory Rigidity and Tumescence Monitor (Dacomed Corp., Minneapolis, USA) provides continuous monitoring of penile rigidity as well as tumescence (Figure 1 ). The rigidity is expressed in percents. For each session the time is monitored when the patient has obtained a rigidity within the limits of the response groups, mentioned below. Details concerning the principles of the device are given by Giesbers et al. The different response groups were as follows: To qualify as an`erectile response' within one of these groups the corresponding rigidity must be obtained for at least three minutes at both the tip and the base of the penis. It has been stated that a rigidity of 70% is demanded for unproblematic completion of coitus. 1 In this study we have chosen 60% as a threshold. We ®nd this acceptable since the aim of the study is a comparison of nitroglycerine and placebo. Furthermore, the values are more easily read and provided with more accuracy when thresholds of 20, 40, and 60% are used.
The study was carried out in two parts; viz. a laboratory study and a home study, both parts were performed as double-blinded, placebo controlled cross-over trials.
Laboratory study
In the ®rst part of the study the patients were seen three times in the out-patient clinic. The ®rst time the effect of intracavernosal papaverine injection of 30 mg was evaluated. The following two sessions the effect of nitroglycerine plasters and placebo plasters Transcutaneous nitroglycerine treatment of erectile dysfunction J Gramkow et al were evaluated in a randomised, double-blinded sequence. Each time the response to the treatment was assessed using the Rigiscan Monitor1. During each session the patients were visually stimulated (three different erotic videos). Since the steady state serum concentration of nitroglycerine is established after approximately 1±2 h the patients were observed for a period of 2 h in both the nitroglycerine and the placebo sessions, but only for 1 h in the papaverine session, due to the earlier onset of the effect after administration of this drug. The placebo and nitroglycerine plasters were applicated to the proximal shaft of the penis and the two loops of the Rigiscan Monitor1 were attached according to the following instructions: one at the base and one at the tip of the penile shaft. Because of the combination of a small penile organ and obesity it was not possible to keep the two loops attached to the penis through a whole session in one patient and he could be evaluated by the use of the Rigiscan Monitor1. This patient was excluded from the study, leaving 18 patients available for the remaining study.
Home study
In the second part of the study the effect of nitroglycerine plasters again were compared to placebo plasters, this time at home, the trial was divided into two periods. The duration of the periods varied from patient to patient according to their sexual activity. In each period the patient should use six plasters. Within each period all plasters contained the same drug (nitroglycerine or placebo). Again the study was designed as a cross-over study and the sequence of the periods was randomised. For each used plaster the patient ®lled in a questionnaire. The duration of time the plaster was used, the effect and possible side effects were described. It was also noted if coitus had been accomplished. The effect was described on a qualitative scale:
Good effect 3points b Moderate effect 2points b No effect 1point
Again the patches were applied on the proximal part of the penile shaft. It was recommended to apply the plaster at least one hour before expected sexual activity.
Statistics
The results have been evaluated using the Wilcoxon±Pratt test.
Ethics
The trial has been approved by the local ethical committee.
Results

Laboratory study
The results of the laboratory study are seen in Figure  2 . Approximately two thirds of the patients in both the nitroglycerine and the placebo session had none or very little effect of the treatment in the laboratory and only three patients in the nitroglycerine session and two patients in the placebo session had an erectile response that could be judged suf®cient for coitus. In contrast, 11 patients had an erectile response that could be judged suf®cient for intercourse following papaverine injection and only four patients had no effect of the injections. The two patients who had an`excellent' response to placebo had`good' and`no' effect respectively to nitroglycerine. The person who responded`excellent' to nitroglycerine had`no effect' to placebo.
It clearly appears that we did not ®nd any statistical difference between treatment with nitroglycerine and placebo (P 0.7656). Treatment with papaverine was superior to both nitroglycerine (P 0.0078) and placebo (P 0.0010).
Home study
As mentioned the patients were supposed to use both six nitroglycerine plasters and six placebo plasters in the home study, but not all patients used Transcutaneous nitroglycerine treatment of erectile dysfunction J Gramkow et al all the plasters. One patient (number 7) did not want to use any of the plasters in the second period as he did not have a sexual partner, this patient was withdrawn from this part of the study. The median score for both nitroglycerine and the placebo plasters was calculated for each patient (Table 2) . Applying a Wilcoxon±Pratt test we found a P-value of 0.2813.
Most of the patients who did not use all plasters explained that they failed to ®nd an opportunity to use all the plasters. One patient did not use his sixth nitroglycerine plaster because of unacceptable side effect (smarting pain). Two patients did not use all the plasters due to lack of con®dence in the effect of the plasters.
Among side effects to treatment with nitroglycerine, headache was by far the most common.
In the home study a total of 99 nitroglycerine plasters and 92 placebo plasters was used. In the ®rst group 35 incidents of headache were reported in relation to the treatment, but the headache was mild in all cases, one female sexual partner did also complain of headache after intercourse. During nitroglycerine treatment 23 incidents of smarting pain at the application site were reported and in one patient the pain was so severe that he did not want to use the plasters any more. A few incidents of¯ushing, palpitations, nausea and vertigo were reported.
In relation to treatment with placebo only one incident with headache and one incident with smarting pain were reported.
Discussion
Meyhoff et al. 2 reported an erectile response in all the ten impotent men tested with a nitroglycerine plaster, and in four of these patients the erectile response was suf®cient for the accomplishment of intercourse after self administration, the study was not blinded nor placebo controlled.
Owen et al 3 reported their results in application of a nitroglycerine paste to the penile shaft in a placebo controlled double-blind study. With the strain gauge technique a signi®cant increase in penile circumference was found.
In a double-blinded cross-over study Claes and Baert 4 reported a complete response to nitroglycerine plaster in 12 out of 26 impotent men.
Sùnksen and Biering-Sùrensen 5 tested nitroglycerine plasters in 17 spinal cord injured men and found an erectile response in 12 of these. Five patients achieved complete response and continued to use the plasters instead of the papaverine injections formerly used.
Conclusion
In the present study no difference between nitroglycerine and placebo has been demonstrated in the treatment of erectile dysfunction. Furthermore it is noted that the effect of nitroglycerine in this study seems to be less compared to the results having been achieved earlier in similar studies. This could indicate that medical treatment had only little effect in the patients who entered this particular study but on the other hand to some degree they have all responded to treatment with papaverine.
The group of patients were very miscellaneous concerning the ethiology of the erectile dysfunction. A penile-brachial index b 60% does not exclude all patients with arteriosclerosis, and by no doubt this ethiology was present in some of our patients.
A P-value of 0.2813 seems very convincing that nitroglycerine does not have an effect in the treatment of erectile dysfunction. But the present study with a sample size of only 18 patients will only reveal a relatively big difference between nitroglycerine and placebo and this difference must be present in the vast majority of the patients. It is well known that the risk of an error of the second kind is more likely the smaller the size of the population and the thinner the line is between the effect of nitroglycerine and placebo. For that reason we can not exclude that nitroglycerine could have some effect in the treatment of erectile dysfunction for some categories of patients.
A new trial including a larger population might reveal some effect, although it might only be for some subgroups of men with erectile failure. Recently some new drugs for oral administration have been introduced and have been reported to be promising in the treatment of impotence. Until the exact effect of these drugs are known further investigation of nitroglycerine is hardly justi®ed. (number of plasters used) number of plasters used) 1 2.00 ± (5) 1.00 ± (6) 2
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Transcutaneous nitroglycerine treatment of erectile dysfunction J Gramkow et al Nevertheless, we still believe that penile applied nitroglycerine has its place in the ®rst phase of the treatment of men with erectile inadequacy before further investigation and invasive treatment is initiated.
